Compare Affirm Holdings Inc (AFRM) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Affirm Holdings Inc vs DexCom, Inc. — how do they compare? Affirm Holdings Inc trades at $76.91 (market cap $25.30B), while DexCom, Inc. trades at $89.53 (market cap $33.08B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Affirm Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AFRM | DXCM | |
|---|---|---|
Market Cap | $25.30B | $33.08B |
Sector | Financials | Health |
52-Week High | $92.18 | $89.53 |
52-Week Low | $42.53 | $54.84 |
Enterprise Value | $31.91B | $32.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFRM trades at $75.25, down 1.74% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $3.22B in 2025, turning profitable with net income of $52.19M, and has beaten EPS estimates in recent quarters. Positive sentiment is driven by analyst optimism and expanding merchant partnerships.
Outlook remains favorable with a consensus price target of $96.00, indicating 28% upside. Risks include high valuation multiples (P/E 68.41) and sensitivity to interest rate changes. Continued execution on growth and profitability will be key for stock performance.
DXCM trades at $84.75, up 2.08% today and near its 52-week high. The stock shows bullish technical momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to 13% year-over-year in Q2 2026, driven by G7 system adoption and international expansion. Cash flow from operations improved to $1.44 billion in 2025, supporting financial flexibility.
Outlook remains positive with raised FY2026 guidance and 80% analyst buy ratings, though valuation multiples like P/E of 33.5 suggest premium pricing. Key risks include competitive pressures in glucose monitoring and reliance on reimbursement policies. The consensus price target of $88.65 implies modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Affirm Holdings Inc
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
